August 2012
-
Impax Laboratories has reported a 19.1% increase in total revenues for the quarter ended September 30, 2014 compared to the third quarter of the prior year. The company attributes a portion of the increase in… Read more . . .
-
Danish instrument manufacturer Ametek Test & Calibration Instruments says that it has worked with “a leading pharmaceutical manufacturer” to develop a semi-automated tester that “detects the firing load and valve breakdown load of one-shot, pressurized… Read more . . .
-
Accordig to Sandoz, the company has received marketing authorization in Estonia, Latvia and Lithuania for the 50-250 and 50-500 µg dosages of the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD. The… Read more . . .
-
Bristol-Myers Squibb could pay a total of up to $444 million to acquire Galecto Biotech and its TD139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), plus potential milestones. The newly announced… Read more . . .
-
Texas-based Mystic Pharmaceuticals has announced that its new Arrowfish intranasal delivery system is now available. The platform, which incorporates Mystic’s VersiDoser and VRx2 blister systems, can deliver either liquid or dry powder formulations, in either… Read more . . .
-
Discovery Laboratories, which is developing Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants, has announced several management changes. Steven G. Simonson, who joined the company in May 2014,… Read more . . .
-
Avanir Pharmaceuticals has published results from the Phase 3 TARGET study of its AVP-825 intranasal sumatriptan powder compared to placebo for the treatment of migraine. The article appears in the January 2015 issue of Headache.… Read more . . .
-
North Carolina-based Cirrus Pharmaceuticals has announced that it will be investing in a new flexible cGMP suite at its facility in Research Triangle Park, NC and will offer new manufacturing services beginning next year. In… Read more . . .
-
CDMO Irvine Pharmaceutical Services has announced that it will open a new 115,000 sq ft analytical facility in Hangzhou, China, the company said. The Hangzhou location should be fully operational in early 2015. While Irvine’s… Read more . . .
-
Computer aided engineering softwared company CD-adapco has released STAR-CCM+ v9.06, with increased accuracy and faster set-up. The software is useful to inhaler and other device designers for realistic modeling of the behavior of aerosols in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland